GLAUKOS Corp director Marc Stapley reported a grant of stock options for 2,987 shares of Common Stock. These options carry an exercise price of $106.52 per share and were granted on May 28, 2026 under the issuer's Director Compensation Policy.
The options vest in full on the one-year anniversary of the grant date and expire on May 28, 2036. This Form 4/A also corrects a prior filing that had mistakenly reported the exercise price as $53.57, confirming the correct price as $106.52.
Glaukos Corp director Aimee S. Weisner received a grant of 2,987 stock options as director compensation. The options have an exercise price of $106.52 per share, were granted on May 28, 2026, and vest in full on the one-year anniversary of the grant date. They are scheduled to expire on May 28, 2036. This amended Form 4 corrects an earlier filing that had reported the exercise price incorrectly, and reflects a routine equity award rather than an open-market stock purchase or sale.
GLAUKOS Corp director Gilbert H. Kliman received a grant of 2,987 stock options, each with an exercise price of $106.52. The options relate to common stock and were awarded under the company’s Director Compensation Policy as part of his board compensation.
This Form 4/A is an amendment to a prior filing that had mistakenly reported the exercise price as $53.57. The options were granted on May 28, 2026, vest in full on the one-year anniversary of the grant date, and expire on May 28, 2036.
GLAUKOS Corp director David F. Hoffmeister received a grant of 2,987 stock options, and the company corrected the reported exercise price. The amended Form 4 updates a prior filing that mistakenly listed the strike price as $53.57; the correct exercise price is $106.52. These options, granted under the issuer’s Director Compensation Policy, vest in full on the one-year anniversary of the May 28, 2026 grant date and are exercisable until May 28, 2036, giving him the right to buy an equal number of common shares at that price.
GLAUKOS Corp director Denice Torres reported a stock option grant and corrected prior disclosure details. She received options for 2,987 shares of common stock at an exercise price of $106.52 per share, granted under the issuer's Director Compensation Policy. The options vest in full on the one-year anniversary of the May 28, 2026 grant date and expire on May 28, 2036. This Form 4/A also amends a prior Form 4 that mistakenly reported the exercise price as $53.57, clarifying that the correct exercise price is $106.52.
Glaukos Corp’s chief development officer Tomas Navratil sold 1,537 shares of common stock in an open-market trade. The sale was executed at an average price of $130.68 per share under a Rule 10b5-1 trading plan adopted on March 12, 2026.
After this transaction, he directly holds 88,833 shares of Glaukos common stock, which includes 39,791 restricted stock units that have not yet vested or been delivered.
Glaukos Corporation submitted a Form 144 notice regarding proposed sales of Common Stock tied to restricted stock vesting and recent dispositions. The filing lists restricted stock vesting entries of 259 shares (11/15/2024), 153 shares (12/13/2024) and 1,125 shares (03/24/2025). It also records recent sales by Tomas Navratil, including 1,031 shares on 03/16/2026 and 2,093 shares on 04/10/2026.
Glaukos Corporation held its annual stockholder meeting and reported voting results on three proposals. Stockholders elected Class II directors Denice M. Torres and Aimee S. Weisner to serve until the 2029 annual meeting, with Weisner receiving 49,397,952 votes for and Torres 40,843,317 votes for. The advisory vote on executive compensation passed, with 47,653,794 votes for and 4,272,830 against. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 54,476,088 votes for and 515,703 against.
GLAUKOS Corp director Leana Wen reported receiving equity compensation on May 28, 2026. She was granted 1,878 restricted stock units under the company’s Director Compensation Policy; these units vest in full one year after the grant and will be settled in an equal number of common shares.
She also received a stock option for 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. After these awards, Wen directly holds 21,617 shares of common stock, which the filing notes include previously granted restricted stock units that are unvested or deferred.
GLAUKOS Corp director Aimee S. Weisner received new equity compensation awards. On May 28, 2026, she was granted 1,878 restricted stock units under the company’s Director Compensation Policy. These units vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of common shares.
She was also granted 2,987 stock options with an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. Following these awards, she holds 20,684 common shares directly, in addition to indirect holdings of 2,000 shares through the Weisner Saeman Family Irrevocable Trust and 29,505 shares through the Saeman-Weisner Family Trust. These are compensation-related grants rather than open-market purchases or sales.